News archive
News Archive Navigation
icon
News Archive Navigation Language
Showing 639 results
April 2018
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval- Patients identified for brolucizumab 12-week treatment interval in Phase III HAWK and HARRIER trials had an 87% and 83% probability of successfully continuing on a 12-week interval through week 48…
-
Media ReleaseNew Novartis Phase III data for brolucizumab demonstrate reliability of 12-week treatment interval
-
Media ReleaseNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home- FocalView is a first-of-its-kind app designed to modernize ophthalmic clinical trials, making them more accessible and flexible- Using patients' self-recorded measurements, FocalView aims to enable…
-
Media ReleaseNovartis launches FocalView app, providing opportunity for patients to participate in ophthalmology clinical trials from home
March 2018
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS-- EXPAND shows oral siponimod (BAF312) is the first investigational disease-modifying therapy in a large trial that meaningfully delayed disability progression in typical secondary progressive MS (…
-
Media ReleasePhase III data in The Lancet show Novartis siponimod significantly improved outcomes in patients with secondary progressive MS
February 2018
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis- Two thirds of patients on Cosentyx® (secukinumab) reported no impact of skin disease on their quality of life over 5 years, SCULPTURE study shows(1)- Study findings show absolute PASI ≤1/≤2/≤3…
-
Media ReleaseNovartis new data show Cosentyx® improved quality of life over 5 years in two thirds of patients with moderate to severe plaque psoriasis
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis- US label updated to include Cosentyx® (secukinumab) data in moderate to severe scalp psoriasis - one of the difficult-to-treat types of psoriasis(1,2)- Approximately half of all 125 million…
-
Media ReleaseNovartis receives FDA approval for Cosentyx® label update to include moderate to severe scalp psoriasis
Pagination
- ‹ Previous page
- 1
- …
- 21
- 22
- 23
- 24
- 25
- 26
- 27
- …
- 54
- › Next page